These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14606355)

  • 1. [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
    Baars A; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2072-6. PubMed ID: 14606355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatofibrosarcoma protuberans: recent clinical progress.
    McArthur G
    Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
    Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
    Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
    Moiseenko VM; Chudenko VA; Orlova RV; Imianitov EN; Matsko DE; Gafton GI; Kochnev VA; Protsenko SA; Mikhaĭlichenko TD; Nogaeva TKh
    Vopr Onkol; 2008; 54(5):656-60. PubMed ID: 19069485
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy.
    Mehrany K; Swanson NA; Heinrich MC; Weenig RH; Lee KK; White CR; Devere TS
    Dermatol Surg; 2006 Mar; 32(3):456-9. PubMed ID: 16640697
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
    Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
    Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
    Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
    [No Abstract]   [Full Text] [Related]  

  • 12. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
    McArthur GA
    Curr Opin Oncol; 2006 Jul; 18(4):341-6. PubMed ID: 16721128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
    Malhotra B; Schuetze SM
    Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
    Han A; Chen EH; Niedt G; Sherman W; Ratner D
    Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
    Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
    J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient.
    Fava P; Stroppiana E; Savoia P; Bernengo MG
    J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):244-5. PubMed ID: 19694892
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.
    Savoia P; Ortoncelli M; Quaglino P; Bernengo MG
    Dermatol Surg; 2006 Aug; 32(8):1097-102. PubMed ID: 16918576
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
    Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
    World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
    Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
    Johnson-Jahangir H; Sherman W; Ratner D
    J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.